



REUTERS

Prozor Biotech to dual list on Tel Aviv bourse

JERUSALEM, May 26 (Reuters) - Israel's Prozor Biotech ([PBTH.A](#)) [PBTH.TA](#) said on Wednesday it would list its shares on the Tel Aviv Stock Exchange starting on Thursday in addition to its current listing on the New York Stock Exchange Amex market.

Wed May 26, 2010 9:22am
EDT

Prozor's chairman, Phillip Frost, in March became chair of Teva Pharmaceutical Industries ([TEVA.O](#)) ([TEVA.TA](#)), the world's largest generic drugmaker.

Prozor is a biopharmaceutical company developing therapeutic proteins including long-acting versions of human growth hormone.

Prozor, formerly called Modigene, will trade under the symbol PBTH and will be included in the mid-cap Tel Aviv 75 index .TA75, broader TA-100 , technology laden Teltech index .TELTECH15 and biomed .BIOMED index.

"We believe this dual listing reflects the company's significant prospects and will provide our stockholders with greater liquidity and the company with greater access to capital, including Israel-focused institutional investors," Shai Novik, Prozor's president, said in a statement. (Reporting by [Steven Scheer](#); Editing by Greg Mahlich)

© Thomson Reuters 2010. All rights reserved. Users may download and print extracts of content from this website for their own personal and non-commercial use only. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters. Thomson Reuters and its logo are registered trademarks or trademarks of the Thomson Reuters group of companies around the world.

Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to colleagues, clients or customers, use the Reprints tool at the top of any article or visit: www.reutersreprints.com.